Director, Division of Cardiometabolic and Endocrine Pharmacology
US Food and Drug Administration
Dr. Shirley Seo is the director of the Division of Cardiometabolic and Endocrine Pharmacology in the Office of Clinical Pharmacology at the FDA. Dr. Seo obtained her Ph.D. in pharmaceutics at the University of Texas at Austin in 2004 where her main areas of research focus were drug metabolism, pharmacokinetics, and immunopharmacology. That same year, she began her FDA career in the Office of Generic Drugs, and in 2007, joined the antivirals teams as a reviewer in the Office of Clinical Pharmacology. In 2012, Dr. Seo became a clinical pharmacology team leader for antiviral products, a position she served for almost 6 years. In her current role as a division director, she is actively engaged in helping guide the development of regulatory policy and overseeing regulatory decision-making for drugs in the following disease areas: cardiology, nephrology, non-malignant hematology, diabetes, dyslipidemia, general endocrinology, bone, reproduction, and urology. Her areas of scientific interest and regulatory expertise include: pediatric pharmacology, complex drug interactions, hepatic drug metabolism and liver diseases, antiviral drug development, and drugs being developed for medical countermeasures. In 2019, she also took on the role of associate editor for Clinical Pharmacology & Therapeutics. Dr. Seo also has a passion for using her knowledge and experiences to help mentor the next generation of scientists.
Friday, March 24, 2023
8:15 AM – 9:15 AM EDT